Vancomycin 초기 투여 용량 개선 방안
Development of Vancomycin Initial Dosage Guidelines to Achieve New Target Ranges
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
In 2009, American Journal of Health-System Pharmacy (AJHP) recommended that targeting vancomycin trough concentrations of 10 mg/L or more because of therapeutic failure and potential risk of developing vancomycin resistance. Therefore, new dosage guidelines that could achieve to these higher target were needed. The aims of this study were to develop dosage guidelines targeting new vancomycin trough concentration and to evaluate the performance of these new guidelines. All data analysis were performed using NONMEM®. Population pharmacokinetic model was first developed from vancomycin dosage and concentration data collected retrospectively during routine therapeutic drug monitoring in 441 patients, then new vancomycin dosage guidelines were developed by using the model to predict vancomycin trough and peak concentrations in a simulated dataset. The estimates, such as, vancomycin concentration trough level, time to achieve target level, mean error were performed to evaluate and compare difference between conventional dosage and new dosage guidelines. The proposed dosage guidelines were predicted to achieve 43.5% of vancomycin trough level within 10~20 mg/L, which is significantly higher than current guidelines (26.3%). Time to achieve target trough level was 19.4 hours in new guidelines comparing to 93.1 hours in the conventional dosage. Thus, new vancomycin dosage guidelines have been developed to achieve new target trough concentrations earlier and more consistently than conventional guidelines.
Abstract
In 2009, American Journal of Health-System Pharmacy (AJHP) recommended that targeting vancomycin trough concentrations of 10 mg/L or more because of therapeutic failure and potential risk of developing vancomycin resistance. Therefore, new dosage guidelines that could achieve to these higher target were needed. The aims of this study were to develop dosage guidelines targeting new vancomycin trough concentration and to evaluate the performance of these new guidelines. All data analysis were performed using NONMEM®. Population pharmacokinetic model was first developed from vancomycin dosage and concentration data collected retrospectively during routine therapeutic drug monitoring in 441 patients, then new vancomycin dosage guidelines were developed by using the model to predict vancomycin trough and peak concentrations in a simulated dataset. The estimates, such as, vancomycin concentration trough level, time to achieve target level, mean error were performed to evaluate and compare difference between conventional dosage and new dosage guidelines. The proposed dosage guidelines were predicted to achieve 43.5% of vancomycin trough level within 10~20 mg/L, which is significantly higher than current guidelines (26.3%). Time to achieve target trough level was 19.4 hours in new guidelines comparing to 93.1 hours in the conventional dosage. Thus, new vancomycin dosage guidelines have been developed to achieve new target trough concentrations earlier and more consistently than conventional guidelines.
참고문헌 (22)
- Moellering RC Jr, "Vancomycin: a 50-year reassessment", Clin Infect Dis, 42(suppl 1), pp.S3~4 (2006)
- Rybak MJ, "The pharmacokinetic and pharmacodynamic properties of vancomycin", Clin Infect Dis, 42(suppl 1), pp.S35~39 (2006)
- Craig WA, "Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid", Infect Dis Clin North Am, 17, pp.479~501 (2003)
- Craig WA, "Pharmacokinetic", pharmacodynamic parameters: rationale for antimicrobial dosing of mice and men, 1998, pp.26, 1~10
- Drusano GL, "Antimicrobial pharmacodynamics: critical interactions of bug and drug", Nature Rev Microbiol, 2, pp.289~300 (2004)
- Rybak MJ, "Pharmacodynamics: relation to antimicrobial resistance", Am J Med, 119(6), pp.S37~44 (2006)
- Moise-Broder PA, "Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus if predictive of failure of vancomycin therapy", Clin Infect Dis, 38, pp.1700~1705 (2004)
- Geraci J, "Vancomycin", Mayo Clin Proc, 52, pp.631~634 (1977)
- American Thoracic Society, "Guidelines for the management of adults with hospital-acquried, ventilator-associated, and healthcareassociated pneumonia: specific evaluation of vancomycin pharmacokinetic indices", Chest, 130, pp.947~955 (2006)
- Boffi El, "High versus standard dose vancomycin for osteomyelitis", Scand J Infect Dis, 36, pp.712~717 (2004)
- Moore MR, "Vancomycin treatment failure associated with heterogeneous vancomycin-intermediate Stapylococcus aureus in a patient with endocarditis and in the rabbit model of endocarditis", Antimicrob Agents Chemother, 47, pp.1262~1266 (2003)
- Rybak M, "Therapeutic monitoring of vancomycin in adult patients: A consensus review of the American Society of Health-System Pharmacists, the Infectious Disease Society of America, and the Society of Infectious Diseases Pharmasists", Am J Health-Syst Pharm, 66, pp.81~98 (2009)
- Sakoulas G, "Effects of prolonged vancomycin administration on methicillinresistant Staphylococcus aureus(MRSA) in a patient with recurrent bacteremia", J Antimicrob Chemother, 57, pp.699~704 (2006)
- Howden BP, "Treatment outcomes of serious infections caused by methicillin resistant Staphylococcus aureus with reduced vancomycin susceptibility", Clin Infect Dis, 38, pp.521~528 (2004)
- "Joint Formulary Committee : British National Formulary, Fifty-sixth Edition", British Medical Association and Royal Pharmaceutical Society of Great Britain, ~ (2008)
- Pea F, "Prospectively validated dosing nomograms for maximizing the pharmacodynamics of vancomycin administered by continuous infusion in the critically ill patients: the Optivanco study", Antimicrob Agents Chemother (2009)
- Thomson AH, "Development and evaluation of vancomycin dosage guidelines designed to achieve new target concentrations", J Antimicrob Chemother (2009)
- Michael EW, "Basic Clinical Pharmacokinetics, 4th ed", pp.451~476 (2004), Lippincott Williams & Wilkins
- Matzke GR, "Pharmacokinetics of vancomycin in patients with various degrees of renal function", Antimicrobial Agents and Chemotherapy, pp.433~437 (1984)
- Yasuhara M, "Population pharmacokinetics of vancomycin in Japanese adult patients", Ther Drug Monit, 20, pp.139~148 (1998)
- Rodvold KA, "Vancomycin pharmacokinetics in patients with varying degrees of renal function", Antimicorb Agents Chemother, 32, pp.848~852 (1988)
- Wang JT, "Necessity of a loading dose when using vancomycin in critically ill patients", J Antimicrob Chemother, 47, pp.239~246 (2001)